Comparative Pharmacology
Head-to-head clinical analysis: CORTRIL versus MEDROL ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTRIL versus MEDROL ACETATE.
CORTRIL vs MEDROL ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortril (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators and suppression of immune response.
Methylprednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators including prostaglandins, leukotrienes, and cytokines.
Hydrocortisone (Cortril) for adrenal insufficiency: 20-30 mg orally daily divided into two or three doses. For acute conditions, IV or IM hydrocortisone sodium succinate 100 mg every 8 hours.
4 to 48 mg orally once daily or in divided doses (e.g., 4 mg every 6 hours) depending on condition, typically starting at 4-48 mg/day. Also intramuscular (IM) as methylprednisolone acetate: 40-120 mg every 1-4 weeks. Intra-articular or soft tissue: 4-40 mg per injection depending on joint size.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours. Clinically, the biologic half-life (duration of ACTH suppression) is longer (8–12 hours).
Terminal elimination half-life of methylprednisolone (active form) is approximately 1.8–3.5 hours. The biological half-life (duration of HPA suppression) is longer: 18–36 hours. Clinical context: Short plasma half-life but prolonged tissue effects due to receptor binding.
Renal (95% as free cortisol and metabolites, primarily tetrahydrocortisol and glucuronide conjugates). Biliary/fecal excretion is minimal (<5%).
Primarily renal (urinary) as inactive metabolites. Approximately 10-20% of the dose is excreted unchanged in urine. Biliary/fecal excretion accounts for <5% of the dose.
Category C
Category C
Corticosteroid
Corticosteroid